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DOI 10.1016/j.ccr.2011.04.010SUMMARYRecurrent fusions of ETS genes are considered driving mutations in a diverse array of cancers, including
Ewing’s sarcoma, acute myeloid leukemia, and prostate cancer. We investigate the mechanisms by which
ETS fusions mediate their effects, and find that the product of the predominant ETS gene fusion,
TMPRSS2:ERG, interacts in a DNA-independent manner with the enzyme poly (ADP-ribose) polymerase 1
(PARP1) and the catalytic subunit of DNA protein kinase (DNA-PKcs). ETS gene-mediated transcription
and cell invasion require PARP1 and DNA-PKcs expression and activity. Importantly, pharmacological inhi-
bition of PARP1 inhibits ETS-positive, but not ETS-negative, prostate cancer xenograft growth. Finally, over-
expression of the TMPRSS2:ERG fusion induces DNA damage, which is potentiated by PARP1 inhibition in
a manner similar to that of BRCA1/2 deficiency.INTRODUCTION
ETS transcription factors are aberrantly expressed in a diverse
array of cancers, including prostate, breast, melanoma, and Ew-
ing’s sarcoma (Jane´-Valbuena et al., 2010; Jeon et al., 1995;
Shurtleff et al., 1995; Sorensen et al., 1994; Tognon et al.,Significance
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664 Cancer Cell 19, 664–678, May 17, 2011 ª2011 Elsevier Inc.2002; Tomlins et al., 2005). In prostate cancer, recurrent gene
fusions of the androgen-regulated gene, TMPRSS2, to the onco-
genic ETS transcription factor ERG are present in approximately
50%of prostate cancers (Brenner andChinnaiyan, 2009; Kumar-
Sinha et al., 2008; Tomlins et al., 2005). Although ERG is the
predominant ETS gene rearrangement observed, other ETSpression occur in about 50% of prostate cancers, transcrip-
o target therapeutically. Here, we show that the ETS:PARP1
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prostate cancer, including ETV1 (Tomlins et al., 2005), ETV4
(Tomlins et al., 2006), and ETV5 (Helgeson et al., 2008). ETS
gene fusions appear early in prostatic disease during the transi-
tion from high-grade prostatic intraepithelial neoplasia (PIN)
lesions to invasive carcinoma (Helgeson et al., 2008; Hermans
et al., 2008; Klezovitch et al., 2008; Tomlins et al., 2007a;
Wang et al., 2008) and are formed by several mechanisms,
including interstitial deletion and genomic insertion (Perner
et al., 2007). In prostate cell lines devoid of the TMPRSS2:ERG
gene fusion, androgen receptor-induced proximity can trigger
topoisomerase-2b-mediated TMPRSS2:ERG gene fusion
formation (Haffner et al., 2010), which is significantly enhanced
by genotoxic stresses such as ionizing radiation (Lin et al.,
2009; Mani et al., 2009).
Once an ETS gene fusion is formed through genomic rear-
rangement, the subsequent overexpression of an ETS gene
fusion protein can contribute to cancer progression through
several different mechanisms. For example, TMPRSS2-ERG
gene fusion expression is required for cell growth in cell line
models that harbor an endogenous gene fusion both in vitro
and in vivo (Helgeson et al., 2008; Sun et al., 2008; Tomlins
et al., 2007a; Wang et al., 2008). Likewise, ETS proteins are
active transcription factors that drive cellular invasion through
the induction of a transcriptional program highly enriched for
invasion-associated genes (Helgeson et al., 2008; Hermans
et al., 2008; Klezovitch et al., 2008; Tomlins et al., 2007a;
Wang et al., 2008). Genetically engineered mice expressing
ERG or ETV1 under androgen regulation exhibit PIN-like lesions
but do not develop frank carcinoma, suggesting that additional
collaborating mutations may be required for de novo carcino-
genesis (Carver et al., 2009; King et al., 2009; Klezovitch et al.,
2008; Kumar-Sinha et al., 2008; Tomlins et al., 2007a; Zong
et al., 2009). Importantly, overexpression of ERG leads to accel-
erated carcinogenesis in mouse prostates with deletion of the
tumor suppressor PTEN (Carver et al., 2009; King et al., 2009).
Additionally, in a transplant model, mouse prostate epithelial
cells (PrECs) that are forced to overexpress both ERG and the
androgen receptor gene form invasive prostate cancer (Zong
et al., 2009). This suggests that ERG rearrangements can func-
tion to accelerate prostate carcinogenesis.
Given the functional consequences of ETS gene rearrange-
ments in prostate cancer progression, a critical question remains
unanswered: Are ETS gene fusions therapeutic targets, either
directly or indirectly? Given the difficulties in targeting nuclear
transcription factors using conventional therapeutic strategies
(Darnell, 2002), we hypothesized that associated enzymes crit-
ical for ERG function may instead serve as viable therapeutic
targets to inhibit ETS-positive prostate cancer cell growth.
RESULTS
Identification of ERG-Interacting Proteins by Mass
Spectrometry
To identify ERG-interacting proteins that may serve as rational
therapeutic targets and explore the mechanism by which ETS
gene fusions mediate their effects, we performed mass spectro-
metric (MS) analysis of proteins that interact with the most prev-
alent ETS gene fusion product, ERG (encoded from TMPRSS2exon 1 fused to ERG exon 2; Tomlins et al. [2005]). VCaP pros-
tate cancer cells (which harbor a TMPRSS2:ERG rearrangement)
or human embryonic kidney (HEK) 293 cells were infected with
either adenoviral V5 or FLAG epitope-tagged ERG expression
vectors, respectively. Immunoprecipitation (IP) was completed
in eight biological replicates to isolate protein-protein interac-
tions as described by schematic (see Figure S1A available on-
line). As expected, the interaction bait, ERG, was the top-scoring
protein identified in the pull-down with 64.4% coverage with 17
tryptic peptides scanned over 500 times (Figure 1A; Table S1).
Interestingly, three of the next four interacting proteins of high
confidence and high sequence coverage identified were compo-
nents of the DNA-dependent protein kinase complex and
included the large catalytic subunit of a phosphatidylinositol 3/
4 (PI3/4)-kinase called DNA-dependent protein kinase (DNA-
PKcs) (10% coverage) and its known interacting subunits Ku70
(26% coverage) and Ku80 (34% coverage) (Figure 1A; Table
S1). Interactions were confirmed with an independent antibody
(Figure S1B), and IPs performed from VCaP cells demonstrated
an endogenous association that occurs in the absence of
ectopic overexpression (Figure 1B; Figure S1C).
To identify additional proteins participating in the ERG:DNAPK
complex, we assessed our list of ERG interactors for other
proteins known to interact with DNA-PKcs, Ku70, or Ku80 and
identified two peptides for poly (ADP-ribose) polymerase 1
(PARP1): VVSEDFLQDVSASTK and QQVPSGESAILDR. Impor-
tantly, we demonstrated that PARP1 endogenously associated
with ERG in VCaP cells (Figure 1B). We then performed reverse
IPs using antibodies against DNA-PKcs, PARP1, and Ku80 and
showed that each antibody was able to detect ERG-V5 protein
(Figure S1D). To detect the PARP1:ERG interaction with the
endogenous TMPRSS2:ERG gene fusion product, we used
agarose-coupled PARP1 antibody to perform the IP-western,
which confirmed that PARP1 interacts with the gene fusion
product in an endogenous setting (Figure S1E).
Because DNA-PKcs only binds with Ku70 and Ku80 in the
presence of DNA (Spagnolo et al., 2006), we tested the depen-
dence of the ERG:PARP1 and ERG:DNA-PKcs interactions on
intact DNA by performing the IP in the presence of 100 mM
ethidium bromide. This treatment disrupted the interaction
between ERG, Ku70, and Ku80, but not the interaction between
ERG and either PARP1 or DNA-PKcs, demonstrating that the
ERG:PARP1 and ERG:DNA-PKcs interactions are DNA indepen-
dent (Figure 1B). As a control, we tested whether ERG would
bind another PI3/4 kinase family member, ATR, or another
protein known to interact with the DNAPK complex, XRCC4.
Consistent with our IP-MS data, we were unable to detect an
interaction between ATR or XRCC4 and ERG by IP-western
blot analysis (Figure S1C and Figure 1B, respectively).
We next assessed whether the ERG:PARP1 and ERG:DNA-
PKcs interactions occur in human prostate cancer tissues.
ERG-IP showed enrichment for DNA-PKcs, Ku70, Ku80, and
PARP1 in ERG gene fusion-positive, but not in ETS gene
fusion-negative, prostate cancer tissues (Figure 1C; Figure S1F).
Interestingly, the lack of detectable ERG:PARP1 interaction in
tissue without ETS gene rearrangement is likely due to the
near-absent ERG expression in rearrangement-negative pros-
tate cancer (Park et al., 2010), as when overexpressed, wild-
type (WT) ERG interacts with PARP1 in cell lines that do notCancer Cell 19, 664–678, May 17, 2011 ª2011 Elsevier Inc. 665
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Figure 1. The TMPRSS-ERG Gene Fusion Product Interacts with PARP1 and the DNA-PK Complex
(A) MS analysis of proteins interacting with ERG. Histograms show peptide coverage of ERG, DNA-PKcs, Ku70, and Ku80.
(B) ERG, DNA-PKcs, PARP1, but not Ku70 or Ku80, interact independent of DNA. IP performed from VCaP cells that naturally harbor the ERG translocation.
(C) ERG, DNA-PKcs, PARP1, Ku70, and Ku80 associate in ERG gene fusion-positive human prostate cancer tissues. Representative ERG-positive and -negative
prostate cancers shown of three pairs of tissues.
(D) Schematic of TMPRSS2-ERG gene fusion tiling deletion expression vectors.
(E) IP of DNA-PKcs, Ku70, Ku80, and PARP1 from HEK293 cells transfected with ERG expression vectors depicted in (D). Input western is shown on the left and
IP-western shown on the right. All IPs were performed with FLAG antibody unless otherwise indicated.
(F) Schematic representation of halo-tagged ERG fragment vectors. The constructs were transcribed using wheat germ extracts, and halo-tagged protein was
purified. Proteins were then incubated with purified DNA-PKcs and IP-westerns were performed. Fragments able to IP DNA-PKcs are indicated with a ‘‘+.’’
(G) Arrow indicates Y373, the amino acid required for the ERG:DNA-PKcs interaction. ETS1:DNA crystal from Garvie et al. (2001) used to demonstrate physical
location of Tyrosine373 (from ERG) relative to the DNA-binding residues. One percent of the total cell lysate used for IP was added to the input lane. Repre-
sentative experiments are shown.
See also Figure S1 and Table S1.
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were performed to test the dependence of the ERG:PARP1 inter-
action on DNA in human prostate cancer tissues. Importantly,
the interaction occurred in the absence of DNA in all three inde-
pendent human tissues (Figure S1H).
Next, we sought to map the interactions and created a series
of flag-tagged ERG expression vectors with tiling deletions,
including: the N terminus (deletion of aa 47–115, predicted
molecular weight 44.6 kDa); pointed domain (aa 115–197,
43.4 kDa); the middle amino acids (197–310, 41.6 kDa); the
ETS domain (aa 310–393, 43.7 kDa); or the C terminus (aa
393–479, 43.6 kDa), and labeled the constructs DN, DP, DM,
DE, and DC, respectively, as depicted in Figure 1D. IP following
transient transfection demonstrated that the interactions
between ERG, DNA-PKcs, Ku70, Ku80, and PARP1 occurred
in the C-terminal half of the ERG protein (Figure 1E). To further
map the ERG:PARP1 and ERG:DNA-PKcs interactions and to
confirm that both PARP1 and DNA-PKcs interact with other
ETS family member proteins, we performed IP-western blot
analysis in HEK293 cells transfected with ERG-FLAG, ETS1-
FLAG, SPI1-FLAG, or ETV1-FLAG expression vectors, which
were selected for their sequence relationship to ERG (Figure S1I).
In all four experiments, pull-downs confirmed the interactions
(Figures S1G and S1J–S1L). We then created N-terminal halo-
tagged expression vectors for in vitro purification of these ETS
genes. Subsequent IP-westerns demonstrated that all four of
these proteins bind directly to DNA-PKcs (Figure S1M). Given
the sequence alignment of these four ETS proteins and the large
tiling deletion data, our data suggested that the interactions
occur through the ETS DNA-binding domain.
To definitivelymap the ERG:DNA-PKcs and ERG:PARP1 inter-
actions, we utilized HALO-tagged WT ERG and six individual
HALO-tagged fragments spanning the entire ERG protein (Yu
et al., 2010). As expected, IP-western blot demonstrated that
the ERG:DNA-PKcs interaction occurred through the ETS
DNA-binding domain. To further map the interaction between
ERG and DNA-PKcs, we utilized a series of three HALO-tagged
fragments that tiled the ETS domain, which localized the interac-
tion to the final 28 amino acids of the ETS domain (Figure 1F; Fig-
ure S1N). Importantly, although, to our knowledge, the crystal
structure of the ETS domain from ERG has not yet been re-
ported, the crystal structure of another ETS factor that we
demonstrated interacts with DNA-PKcs, ETS1, has been pub-
lished (Garvie et al., 2001). Based on homology with other inter-
acting ETS proteins and structural information, we predicted that
the interaction was dependent on the amino acids, YYDKN. By
site-directedmutagenesis of each residue to alanine, we demon-
strated that the Y373A mutant was unable to precipitate DNA-
PKcs, suggesting that this interaction is mediated by Tyrosine
373 (Figure 1F; Figure S1P). Analysis of the ETS1 structure
shows that Y373 is adjacent to the arginine residues that fit
into the DNA groove and that Y373 is accessible to potential in-
teracting proteins (Figure 1G).
After demonstrating that ERG interactswithDNA-PKcsdirectly
through amino acid Y373, we sought to map the ERG:PARP1
interaction. However, purified ERG was only able to interact
with purified PARP1 in the absence of ethidium bromide (Fig-
ure S1O). Because the interaction occurred in cells independent
of ethidium bromide, this suggests that the ERG:PARP1 interac-tion is mediated by other proteins. This is consistent with the
results from our IP-MS experiment in which few PARP1 peptides
were identified, suggesting that the ERG:PARP1 interaction is
mediated by an intermediate protein such as DNA-PKcs.
PARP1 and DNA-PKcs Are Required for ERG-Mediated
Transcription
Given that the interaction of DNA-PKcs and PARP1 with ERG
occurs through the ETS domain, we hypothesized that both
PARP1 and DNA-PKcs function as coregulators of ERG tran-
scriptional activity. Thus, we performed chromatin immunopre-
cipitation (ChIP) assays in VCaP cells and assessed enrichment
of known ERG targets, including the PLA1A promoter and the
FKBP5, PSA, and TMPRSS2 enhancers. These experiments
demonstrated that ERG, DNA-PKcs, activated DNA-PKcs
(assessed by T2609 phosphorylation), Ku70, Ku80, and PARP1
bind to these sites, but not to the negative control gene
KIAA0066 (Tomlins et al., 2008) (Figure S2A). Interestingly, this
enrichmentwasdisruptedbyERGsiRNA (Figure 2A; Figure S2B),
supporting amodel in which ERG recruits PARP1 andDNA-PKcs
to specific genomic loci during transcription (Figure 2B). Consis-
tent with this hypothesis, serial ChIP reactions (ERG, then PARP1
or DNA-PKcs) demonstrated that an ERG:PARP1 complex and
an ERG:DNA-PKcs complex are both present at ERG-regulated
loci (Figure S2C). Although it was not possible to perform re-ChIP
experiments with the PARP1 and DNA-PKcs antibodies, IP-
western blot analysis confirmed that PARP1 and DNA-PKcs
interact in a DNA-independent manner in VCaP cells (Fig-
ure S2D). Likewise, this experiment suggests that DNA-PKcs
binding to ERG does not disrupt the ERG:DNA interaction.
To test whether DNA-PKcs and PARP1 are required for ERG-
mediated transcriptional activation, we constructed a PLA1A
promoter reporter. Transfection of the reporter into RWPE cells
treated with either LACZ or ERG adenovirus and siRNA (Fig-
ure S2E) indicated that both DNA-PKcs (p = 1.99 3 103) and
PARP1 (p = 2.37 3 103) are required for ERG-induced activa-
tion of PLA1A (Figure S2E) in RWPE cells. In contrast, inhibition
of the related PI3/4-like kinase, ATM, had no significant effect on
ERG activity.
Although ATM and ATR repair DNA strand breaks through
different pathways, DNA-PKcs is specifically required for nonho-
mologous end-joining (NHEJ) (Weterings andChen, 2007). In this
process, DNA-PKcs, Ku70, and Ku80 form a complex on the
broken DNA end that facilitates DNA end processing and rejoin-
ing in a multistep procedure that requires the XRCC4/DNA
Ligase IV complex. In fact, XRCC4 and DNA Ligase IV are both
independently required for execution of NHEJ in mammalian
cells because targeted inactivation of either gene leads to
NHEJ defects in mouse cells (Barnes et al., 1998; Frank et al.,
1998). Subsequently, we used siRNA to knockdown XRCC4
(Figure S2E) to evaluate the necessity of effective execution of
NHEJ for ERG-induced transcriptional activation of the PLA1A
promoter. Because knockdown of XRCC4 had no effect on
ERG activity, the experiment further suggests a NHEJ-indepen-
dent role for DNA-PKcs in ERG-mediated transcription
(Figure S2E).
Given the importance of PARP1 and DNA-PKcs for ERG-
mediated transcription, we sought to explore the global effects
of inhibiting PARP1 and DNA-PKcs on the ERG transcriptome.Cancer Cell 19, 664–678, May 17, 2011 ª2011 Elsevier Inc. 667
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Figure 2. PARP1 and DNA-PKcs Are Required for ERG-Regulated Transcription
(A) ChIP of PARP1 and the DNAPK complex shows an association with ERG-regulated targets, including the PLA1A promoter as well as FKBP5, PSA, and
TMPRSS2 enhancers, but not the negative control gene KIAA0066. ChIPs were performed in VCaP cells treated with control or one of two independent ERG
siRNAs for 48 hr prior to crosslinking.
(B) ChIP performed as in (A) but with stable RWPE-ERG or -LACZ cells.
(C) Data from gene expression arrays were analyzed by molecular concept mapping. The gene set analyzed is the set of genes that was greater than 2-fold
differential in all three siRNA treatments relative to control. This gene set was used to determine the correlation of genes regulated by ERG, DNA-PKcs, and
PARP1 in VCaP cells with published microarray data. Node size is proportional to the number of genes in the set, and edges represent statistically significant
associations (p < 0.01). Arrow directionality represents gene sets either being induced or repressed.
(D) VCaP cells were treated with siRNA as indicated 48 hr prior to RNA isolation. qPCR was then run to confirm gene expression changes identified in the mi-
croarray experiment. Data are shown as a heat map with siRNA treatments along the x axis and genes expression analyzed by qPCR along the y axis. Shades of
green represent downregulation of gene expression, whereas shades of red represent upregulation.
(E) VCaP cells were treated with either NU7026 or Olaparib for 48 hr as indicated, and qPCR analysis of ERG target genes identified from gene expression
microarray experiment was performed.
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Cancer Cell
PARP1 Inhibition in ETS Positive Prostate CancerTo do this, we used Agilent Whole Genome Oligo Expression
Arrays to profile RNA from VCaP cells treated with either DNA-
PKcs or PARP1 siRNA (knockdown confirmed in Figure S2I).
Our analysis revealed 50 and 252 unique features that were
greater than 2-fold down- and upregulated, respectively, in
both the PARP1 and DNA-PKcs siRNA-treated samples (Table
S2). Venn diagram analysis was used to show the overlap of
differential gene sets to genes regulated by ERG in VCaP cells
(Tomlins et al., 2008) (p < 0.0001 for all interactions unless indi-
cated, hypergeometric test) (Figures S2F and S2G). To then
understand how this gene signature is related to existing signa-
tures, we uploaded our expression signature into Oncomine
Concepts Map (OCM) (Rhodes et al., 2007; Tomlins et al.,
2007b) to identify human tissue gene signatures that are en-
riched for genes upregulated by DNA-PKcs and PARP1 siRNA
in VCaP cells (genes repressed by PARP1 and DNA-PKcs).
This provided unbiased validation that the tissue-based gene
signatures most highly enriched with our gene set were the
genes repressed in ETS-positive as compared to ETS-negative
prostate cancer: Tomlins et al. (2007b) (OR = 3.08, p = 1.40 3
1015) and (OR = 2.91, p = 3.30 3 1010); and Lapointe et al.
(2004) (OR = 3.33, p = 2.30 3 106) (Figure 2C). Interestingly,
the gene signature also showed significant overlap with the set
of genes repressed in metastatic as compared to localized pros-
tate cancer, suggesting that repression of these genes is impor-
tant for prostate cancer progression: OR = 2.99, p = 1.53 1010
(Vanaja et al., 2003); OR = 3.31, p = 1.503 106 (LaTulippe et al.,
2002) (Figure 2C). Treatment of VCaP cells with siRNA confirmed
gene expression changes as predicted by the gene expression
arrays (Figure 2D), as did treatment with either the small mole-
cule DNA-PKcs kinase inhibitor, NU7026, or the small molecule
PARP1 inhibitor, Olaparib (Figure 2E). Analysis of siRNA-treated
RWPE-ETV1 cells (Figure S2J) confirmed that DNA-PKcs and
PARP1 regulated ETV1 transcriptional activity aswell (Figure 2F).
Taken together, these data suggest that PARP1 and DNA-PKcs
play a role in modulating transcriptional activity of a number of
ETS target genes, some of which are differentially expressed
between localized and metastatic disease.
PARP1 and DNA-PKcs Are Required for ERG-Mediated
Cell Invasion, Intravasation, and Metastasis
Inhibition of PARP1 and DNA-PKcs altered ERG transcriptional
activity of several progression-associated genes such as
EZH2. Here, we tested the role of these enzymes in ERG-
induced cell invasion. Both DNA-PKcs siRNA (Figures S2H and
S2I) and NU7026 attenuated invasion in RWPE cells transduced
with ERG (Figure 3A) and VCaP cells (Figure 3B) (p < 0.01 for
DNA-PKcs siRNA or NU7026 >10 mM). Likewise, we found that
treatment with either PARP1 siRNA (Figures S2H and S2I) or Ola-
parib led to a significant reduction in ERG-driven RWPE and
VCaP cells invasion (Figures 3A and 3B) (p < 0.05 for all
PARP1 siRNA or Olaparib treatments). As with our analysis of
ERG-mediated transcription, knockdown of either ATM or
XRCC4 did not have an effect on ERG-mediated invasion
(Figures 3A and B). Treatment of stable RWPE cells stably over-(F) As in (D) except stable RWPE-ETV1 cells were used. All qPCR experiments we
otherwise indicated.
See also Figure S2 and Table S2.expressing ETV1 (Tomlins et al., 2007a) with PARP1 or DNA-
PKcs siRNA (Figure S2J) or small molecule inhibitors also led
to a significant reduction in invasion (p < 0.01 for all PARP1 or
DNA-PKcs treatments) (Figure 3C). However, importantly,
invasion of two negative control models, the ETS rearrange-
ment-negative cell line PC3 and RWPE cells overexpressing an
alternative prostate cancer gene fusion, SLC45A3-BRAF, was
not affected by inhibiting either enzyme (Figure 3D; Figure S2K).
To determine if the observed loss of cell invasion was due to
cytotoxicity, we performed chemosensitivity assays with both
Olaparib and NU7026. Neither Olaparib nor NU7026 had an
effect on the in vitro cell proliferation rate of any of the cell lines
tested, suggesting that the reduction in cell invasion is not due to
changes in cell proliferation (Figure S3A). In fact the EC50 for both
drugs was well beyond the dose shown to block transcription
and invasion (Figures S3B and S3C).
We next sought to define the role of PARP1 in ERG-mediated
invasion and intravasation in vivo. To do this, we implanted cells
onto the upper chorioallantoic membrane (CAM) of a fertilized
chicken embryo and analyzed the relative number of cells that
invade and intravasate into the vasculature of the lower CAM
3days after implantation (Kim et al., 1998). In this assay, Olaparib
blocked both ERG-mediated invasion and intravasation (p < 0.1)
(Figures 4A and 4B). Because increased expression of EZH2
alone is sufficient to drive metastasis in several different cell
systems, we monitored EZH2 mRNA expression and found
that EZH2 expression was downregulated following either
PARP1 or DNA-PKcs inhibition (Figure S4A), suggesting that
mechanistically, PARP inhibition disrupts ERG-mediated inva-
sion and intravasation by inhibiting ERG-mediated transcrip-
tional activation of invasion-associated genes such as EZH2.
However, more importantly, our models suggested that thera-
peutic disruption of either ERG-interacting enzymes (PARP1 or
DNA-PKcs) inhibits the metastatic spread of prostate cancers
harboring ETS gene fusions.
To test this postulate, we analyzed the metastatic potential of
an ETS-positive (LNCaP) and an ETS-negative (PC3) cell line. As
shown in Figure 4C, Olaparib treatment blocked the formation of
livermetastases fromLNCaP (p = 0.01), but not PC3 cells. Impor-
tantly, we also noticed that over the extended treatment period,
the ETS-positive tumors were significantly smaller than the ETS-
negative tumors (Figure 4D), with p < 0.05 for VCaP and p < 0.01
for LNCaP. This suggests that PARP1 could play a role in the
long-term maintenance of ETS-positive cancer cell survival.
Because it appeared that the long-term survival of ETS-overex-
pressing tumors can be diminished by treatment with Olaparib,
we sought to compare the magnitude of effect to that of a clini-
cally validated model. Therefore, we xenografted HCC1937
(BRCA1 mutant) and MDA-MB-231 (BRCA1/2 WT) cell lines,
and following Olaparib treatment a significant effect was
observed on the BRCA1 mutant HCC1937 tumors, whereas no
measurable effect was observed in MDA-MB-231 tumors.
Surprisingly, the magnitude of effect observed in the HCC1937
cells was equivalent to the magnitude of effect observed in the
two ETS-positive cell line xenografts (Figure 4D).re run three times in quadruplicate. All bar graphs are shown with ±SEM unless
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Figure 3. ERG-Mediated Invasion Requires Engagement of PARP1 and DNA-PKcs
(A) RWPE cells were infected with ERG adenovirus and treated with indicated siRNAs or different doses of the DNA-PKcs inhibitor, NU7026, or the small molecule
PARP1 inhibitor, Olaparib, for 48 hr prior to plating cells in Matrigel-coated Boyden chambers. After another 48 hr, cell invasion was quantified.
(B) As in (A) except VCaP cells.
(C) As in (A) except stable RWPE cells transduced with ETV1 lentivirus.
(D) As in (A) except PC3 or RWPE-SLC45A3-BRAF cells. Representative of three independent experiments. Representative photomicrographs of invaded cells
are shown (lower Boyden chamber stained with crystal violet). For all experiments mean ± SEM is shown (*p < 0.05, **p < 0.01).
See also Figure S3.
Cancer Cell
PARP1 Inhibition in ETS Positive Prostate CancerETS Gene Fusion Prostate Tumors Are Preferentially
Susceptible to PARP1 Inhibition In Vivo
Based upon our in vivo data from the chicken CAM assay, we
hypothesized that inhibition of PARP1 would inhibit ETS-positive
prostate cancer growth in mouse xenograft models. Several
PARP inhibitors have entered phase I and phase II clinical trials
(Audeh et al., 2010; O’Shaughnessy et al., 2011; Tutt et al.,
2010). One of these, Olaparib, was shown to be well tolerated
with a minimal side effect profile in patients with cancer670 Cancer Cell 19, 664–678, May 17, 2011 ª2011 Elsevier Inc.(Fong et al., 2009). Thus, to first test our hypothesis, we im-
planted VCaP (ERG positive) or PC3-LACZ (ETS negative) cells
and studied the impact of Olaparib (100 mg/kg/day, IP) on xeno-
graft growth. Importantly, we observed a significant reduction
of tumor growth in the ETS-rearranged cell line relative to that
of the vehicle control, but no change was observed in the
ETS-negative control cell line (p = 0.002 for VCaP cells), suggest-
ing preferential sensitivity of ETS-positive tumors (Figures S5A
and S5B).
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Figure 4. ERG-Mediated Invasion, Intravasation, and Metastasis Require PARP1 Activity In Vivo
(A) CAM invasion assay performed using stable RWPE-LACZ, or RWPE-ERG cells labeled with microspheres (green fluorescence emission) and treated with or
without a single dose of Olaparib (40mg/kg) as indicated. Seventy-two hours after implantation, the upper CAMwas harvested. Frozen sectionswere created and
stained for hematoxylin and eosin (top row), human-specific cytokeratin (immunohistochemistry, middle row), or chicken-specific type IV collagen (red immu-
nofluorescence, bottom row). Arrowheads indicate cells invaded through the upper CAM. Representative images are shown. Scale bars, 200 mM.
(B) CAM intravasation assay performed using stable RWPE-ERG cells pretreated with siRNA as indicated. Alternatively, RWPE-ERG cells were implanted and
treated with a single dose of Olaparib immediately after implantation (40 mg/kg). Seventy-two hours after implantation, the lower CAMwas harvested. Total DNA
was isolated from the lower CAM, and qPCR was performed using human-specific ALU PCR primers. Total cell number was determined by comparing to
a standard curve created using varying amounts of RWPE cells as input.
(C) Liver metastasis in chicken embryos was assessed 8 days following implantation of either LNCaP (ETV1 rearrangement) or PC3 (no ETS rearrangement) cells
onto the upper CAM. Animals were injected every other day with Olaparib (40 mg/kg) prior to harvesting chicken livers. Total cell number was then quantified by
qPCR as in (B).
(D) ETS-positive (VCaP and LNCaP) and ETS-negative (PC3 and 22RV1) prostate cancer cells as well as BRCA1 mutant (HCC1937) and BRCA1/2 WT (MDA-
MB-231) breast cancer cells were implanted onto the upper CAM. These cell line xenografts were then treated with 40mg/kg Olaparib every other day for 8 days.
Tumors (noninvaded cells remaining on the upper CAM) were collected and weighed. Average tumor weight is shown. For all experiments mean ± SEM is shown
(*p < 0.05).
See also Figure S4.
Cancer Cell
PARP1 Inhibition in ETS Positive Prostate CancerWe then extended our experiment to analyze the effects of
Olaparib on a panel of ETS-positive and ETS-negative prostate
cancer cell lines, including an isogenic model. Because this
experiment intended to test the specificity of Olaparib-induced
growth inhibition for ERG-overexpressing prostate xenografts,we chose to use a dose similar to that used in previously pub-
lished xenograft experiments (Rottenberg et al., 2008). Consis-
tent with our hypothesis, this dose of Olaparib had a significant
effect on VCaP cells (p = 0.001) but did not inhibit the growth
of two additional ETS-negative cell line xenografts (22RV1 orCancer Cell 19, 664–678, May 17, 2011 ª2011 Elsevier Inc. 671
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Figure 5. Inhibition of PARP1 Alters ETS-Positive, but Not ETS-Negative, Cell Line Xenograft Growth
(A–F) Specificity screen for ETS-positive and ETS-negative tumor cell line xenografts. Cell lines were injected subcutaneously and grown until tumors were
palpable. Xenograftedmice then received i.p. injections of Olaparib 40 mg/kg as indicated 5 days/week. Caliper measurements were taken weekly. ETS-positive
cell line xenografts were (A) VCaP (ERG rearrangement) and (F) PC3-ERG cells, and the ETS-negative xenografts were (B) 22RV1, (C) DU145, and (D and E)
PC3-Control/-LACZ, respectively.
(G) Mice xenografted with VCaP cells were treated as in (A) except with 100 mg/kg Olaparib and/or 50 mg/kg TMZ as indicated. Olaparib was administered i.p.
5 days/week. TMZ was administered in two 5 day cycles with the first occurring during week 3 and the second occurring during week 5. For all experiments
mean ± SEM is shown (*p < 0.01 unless indicated).
See also Figure S5.
Cancer Cell
PARP1 Inhibition in ETS Positive Prostate CancerDU145) (Figures 5A–5C). This experiment also demonstrated
that the VCaP tumor growth response was dose dependent.
To then create an isogenic model, we overexpressed the primary
TMPRSS2:ERG gene fusion product in the PC3 prostate cancer
cell line (PC3-ERG). Western blotting confirmed protein overex-
pression, and IP-western confirmed the ERG:DNA-PKcs and672 Cancer Cell 19, 664–678, May 17, 2011 ª2011 Elsevier Inc.ERG:PARP1 interactions (Figures S5C and S5D). ChIP assays
demonstrated that ERGbinds to known target genes in PC3 cells
(Figure S5E), and qPCR demonstrated ERG transcriptional
activity (Figure S5F). Surprisingly, ERG overexpression led to
a slightly reduced growth rate of PC3 cells relative to LACZ-over-
expressing PC3 cells (Figure S5G). Consistent with the model
Cancer Cell
PARP1 Inhibition in ETS Positive Prostate Cancerthat ETS-positive, but not ETS-negative, prostate tumors are
susceptible to PARP inhibition, overexpression of ERGwas suffi-
cient to significantly sensitize PC3 cells to PARP inhibition (p =
0.007), suggesting that ERG overexpression provides a selective
mechanism for Olaparib-mediated growth inhibition (Figures
5D–5F). Western blot and qPCR analysis of flash-frozen, staged
PC3-ERG tumors treated with or without drug for 4 hr confirmed
inhibition of PARP1 activity and loss of ERG-target gene expres-
sion after treatment with Olaparib (Figures S5H–S5K). In line with
the clinical observation that Olaparib is well tolerated at doses
capable of inhibiting PARP activity (Fong et al., 2009), Olaparib
treatments in our xenograft models did not lead to a significant
decrease in total body weight and did not lead to liver toxicity,
as assessed by serum levels of alanine aminotransferase (ALT)
and aspartate aminotransferase (AST) (Figure S5L).
Given the specific effect of Olaparib on ERG-positive cell line
xenograft growth (Figure S5M), we extended our analysis with
the use of a model of primary human prostate tumors maintained
in serial xenografts (Li et al., 2008). We identified one ERG-posi-
tive (MDA-PCa-133), one ETV1-positive (MDA-PCa-2b-T) (FISH
confirmed; Tomlins et al., 2007a), and one ETS-negative (MDA-
PCa-118b) model for this experiment by assessing relative levels
of ETS gene expression by qPCR (Figure S5N). Functional ETS
gene status was assessed by testing the relative expression of
several ETS target genes, including EZH2, DNMT3a, ZNF100,
PBX1, ZNF618, PLA1A, and PLAT, between the models (Fig-
ure S5O). As shown in Figures S5P and S5Q, low-dose Olaparib
altered the growth of both the ERG and ETV1-overexpressing
primary human prostate cancer xenografts (MDA-PCa-133: p =
0.05 [day 8] and p < 0.01 [days 12, 16, 20, 24, 28, and 32];
MDA-PCa-2b-T: p < 0.01 [days 8, 12, and 16]) but had no effect
on the ETS-negative primary human xenograft model (Fig-
ure S5R). In all cases, Olaparib did not have an observable effect
on total body weight (Figures S5S–S5AA).
Because we were able to validate the hypothesis that Olaparib
specifically alters the growth of either ETS-overexpressing or
BRCA1/2-deficient cell lines, we sought to extend the treatment
regimen to identify combination therapies that enhance the
magnitude of inhibition without causing significant toxicity.
Recently, an alkylating agent called temozolomide (TMZ) has
been shown to potentiate the effects of other PARP inhibitors
in several cancer xenograft models (Donawho et al., 2007; Liu
et al., 2008; Palma et al., 2009) as well as caused a complete
or partial response in some patients enrolled in a phase II trial
for metastatic breast cancer (S.J. Isakoff et al., 2010, J. Clin. On-
col., abstract). As expected, the combination treatment resulted
in a significant growth reduction of VCaP tumors that was main-
tained over the entire 6weeks (p < 0.001 for all combination treat-
ments) (Figure 5G). Even with the combination therapy, at this
dose range, no overt toxicity such as excessive weight loss
was observed (Figure S5AB). This suggested that the addition
of PARP inhibitor therapy to existing chemotherapeutic regimens
will help enhance the overall effect for ETS-positive tumors.
ETS Transcription Factors Drive DNA Double-Strand
Break Formation
To explore potential mechanisms of ETS-specific therapeutic
response to these inhibitors of DNA repair, we assessed total
levels of DNA double-strand breaks in vitro. We hypothesizedthat constitutive overexpression of ERG may lead to an
increased susceptibility to DNA damage. Thus, we first assessed
the total levels of a histone mark of DNA double-strand breaks
called g-H2A.X in Olaparib-treated versus untreated VCaP cells.
Surprisingly, the untreated cells had a high level of g-H2A.X foci
(Figure 6A), leading us to test the hypothesis that overexpression
of ETS genes induces DNA double-strand breaks. Overexpres-
sion of ETS genes in primary PrECs induced >5 g-H2A.X foci in
greater than 75% of the analyzed cells, whereas the control
genes LACZ and EZH2 had no effect (Figures 6A and 6B). Quan-
titative PCR confirmed overexpression (Figures S6A–S6C). Like-
wise, other ETS genes were also capable of inducing g-H2A.X
foci in several different prostate cell lines (Figures S6D and
S6E). To then confirm that ERG induces g-H2A.X foci in an
endogenous setting, we depleted ERG from VCaP cells by
RNA interference (Figure S6I) and found a significant decrease
in the average number of g-H2A.X foci (p = 7.16 3 103 and
p = 1.36 3 103) for two independent siRNAs, respectively
(Figures 6A and 6B). Although g-H2A.X foci represent an early
mark of DNA-damage recognition, 53BP1 is present only in the
later stages of repair (Bennett and Harper, 2008). As such, in
the presence of a DNA-damage response, we expected to
observe an increase in 53BP1 foci formation. Indeed, the ETS
genes also induced 53BP1 foci formation (Figures 6A and 6B;
Figure S6D).
After demonstrating that ETS gene overexpression drives the
accumulation of markers of DNA double-strand breaks, we
sought to confirm the presence of DNA double-strand breaks
by directly analyzing cellular DNA for fragmentation using the
COMET assay. As with the g-H2A.X and 53BP1 foci formation
assays, in PC3 cells, ERG or ETV1 overexpression was sufficient
to induce significantly longer and brighter tails than those
observed in controls (p < 0.01 for both ETS genes), and treat-
ment with either ERG siRNA led to a reduction in relative level
of DNA double-strand breaks (p < 0.01) (Figures 6C and 6D).
Olaparib Potentiates ETS-Induced DNA Damage
After finding that aberrantly expressed ETS transcription factors
drive the accumulation of DNA double-strand breaks, we
hypothesized that by having a baseline level of DNA damage,
ETS-positive cancers may be specifically susceptible to accu-
mulating DNA damage following inhibition of the interacting
DNA-repair enzyme PARP1. To test this hypothesis, we analyzed
VCaP cells treated with Olaparib for 48 hr. Olaparib-treated
VCaP cells had a very high level of g-H2A.X foci (Figure S6F).
Importantly, by depleting endogenous ERG using either of two
independent siRNAs (confirmed in Figure S6I), we were able to
reverse the gross increase in g-H2A.X. Similar increases in foci
were observed in PC3-ERG cells or PC3 cells with BRCA2
knockdown, but not in the control cells (Figure S6F). Knockdown
efficiency was confirmed by qPCR (Figure S6G). Quantification
of the relative levels of DNA double-strand breaks demonstrated
that, whereas there was an increase in the tail moment of all Ola-
parib-treated cell lines, Olaparib caused a significantly greater
increase in the tail moments of ERG-positive cells than controls
(p < 0.001, two-way ANOVA) (Figures 6C and 6D). In conjunction
with this observation, both ERG siRNAs led to a significant
reduction in DNA damage following Olaparib and blocked the
synergistic increase of DNA damage observed with OlaparibCancer Cell 19, 664–678, May 17, 2011 ª2011 Elsevier Inc. 673
APr
EC
LACZ ERG
Control siRNA ERG siRNA 1
V
C
aP
Mock
Mock
M
oc
k
Co
nt
ro
l
siRNA
ER
G
_1
M
oc
k
LA
CZ
EZ
H
2
ET
V1
ER
G
VCaP
PrEC
0
25
50
75
100
%
 c
el
ls 
>5
 fo
ci
γH2A.X
53BP1
B
D
LA
CZ
ER
G
Mock 10μM Olaparib
LA
CZ
ER
G
ET
V1
Co
nt
ro
l
BR
CA
2_
1
BR
CA
2_
2
ER
G
_1
PC3
siRNA 
treated
Co
nt
ro
l
CO
M
ET
 
Ta
il 
M
om
en
t
sh
BR
CA
2
C
145
118
78
69
38
0
39
26 59
86
46
9
PC
3
V
C
aP
 +
 s
iR
N
A
Co
nt
ro
l
ER
G
_1 231
48 68
14792
7938
0
50
100
150
M
oc
k
M
oc
k
shRNA
VCaP
Control Olaparib
E
TMPRSS2 ERG
ERG
overexpression
H2A.X
p
PARP1
DNA-PKcs
ERGKu80
Ku70
DNA Breaks
Transcriptional program 
Invasion
Metastasis
Δ
Olaparib
****
**
ER
G
_2
**
H
C
C
19
37 57
150
10
27
Mock 10μM Olaparib
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•••
•
•
•
•
•
•
•
•
•
•••
•
•
•
•
•
•
•
•
•
•••
•
•
•
•
•
•
•
•
•
•
•
••
•
•
•
•
•
•
•
•
•
•
••
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
••
•
•
•
ER
G
_2
H
CC
19
37
**
**
**
**
Figure 6. ETS Transcription Factors Induce DNA Damage that Is Potentiated by PARP Inhibition
(A) g-H2A.X immunofluorescence staining shows that ERG induces the formation of g-H2A.X foci. Top row shows benign PrECs were infected with lentiviruses
expressing LACZ or ERG. Bottom row illustrates VCaP cells treated with control siRNA or ERG siRNA.
(B) Quantification of g-H2A.X and 53BP1 immunofluorescence staining in PrEC or VCaP cells. For all experiments mean ± SEM is shown (**p < 0.01).
(C) ETS overexpression or BRCA2 knockdown (with shRNA) induces DNA damage as assessed by neutral COMET assay in VCaP cells. Cells were treated with or
without 10 mMOlaparib for 48 hr. Cells with DNA damage have an extended ‘‘tail moment’’ of fragmented DNA shown in red. Relative tail length is shown in white.
Representative images showing quantification of head and tail height, length, and fluorescence intensity are shown (as indicated).
(D) Quantification of average COMET tail moments following treatment as noted in the box plot. Statistical tests were performed using the two-way ANOVA test
(described in Supplemental Experimental Procedures) to determine if the increase in DNA damage in Olaparib-treated ETS-overexpressing cells (PC3-ERG,
PC3-ETV1, and VCaP) was statistically greater than the increase observed in Olaparib-treated control cells with low ETS expression (PrEC-LACZ, PC3-LACZ, or
VCaP treated with ERG siRNA) as indicated in the text. Similar statistical tests were used to compare the increase in BRCA2 shRNA-expressing cells to PC3 cells
transduced with control shRNA (**p < 0.01).
(E) Proposed model to therapeutically target ETS gene fusions via their interacting enzyme, PARP1. All bar graphs are shown with ±SEM unless otherwise
indicated.
See also Figure S6.
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two-way ANOVA). Consistent with this observation, the BRCA1
mutant HCC1937 breast cells and PC3 cells with BRCA2 shRNA
underwent a significant increase in the total levels of DNA
damage when treated with Olaparib. Taken together, these
data demonstrate that similar to BRCA1/2-deficent tumors,
ETS-positive, but not ETS-negative, prostate cancer models
are susceptible to PARP inhibition through the increased inci-
dence of DNA double-strand breaks (Figure 6E).
To discriminate between mechanisms of ERG-potentiated
DNA damage, we performed the COMET assays after 0.5, 1,
24, and 48 hr exposure to Olaparib. Surprisingly, the potentiated
DNA damage was observed in PC3-ERG cells relative to PC3-
LACZ cells as early as 30 min after treatment (Figure S6H) (p =
0.002 at 30 min, two-way ANOVA). This suggested that the
mechanism of ERG-induced potentiation is independent of the
genes regulated by PARP1-mediated transcriptional activation.
Focused expression analysis of genes involved in DNA-damage
repair pathways demonstrated no significant change in any of
the repair genes analyzed, suggesting that the DNA-damage
phenomenon is independent of changes to ERG-regulated
gene expression (Figure S6I). To analyze the role of repair path-
ways directly, we tested the postulate that downregulation of
a protein critical for the execution of NHEJ pathway such as
XRCC4 would lead to a synergistic induction of DNA damage
in a homologous recombination (HR)-deficient cell. Treatment
of HR-deficient HCC1937 cells with siRNA confirmed a greater
increase in DNA damage following XRCC4 knockdown (NHEJ)
than by XRCC3 knockdown (HR) (p < 0.05, one-way ANOVA).
In contrast, the synergistic induction of DNA damage following
XRCC4 or XRCC3 knockdown was not observed in PC3-ERG
cells as compared to PC3-LACZ cells (Figures S6J and S6K).
This suggested that ERG overexpression does not completely
block either of these double-strand break repair pathways.
This was further confirmed by HR-efficiency assays that demon-
strated that HR is not significantly altered by ERG overexpres-
sion (Figure S6L).
DISCUSSION
In this study we discovered that the ETS gene fusion product,
ERG, physically interacts with the enzymes PARP1 and DNA-
PKcs. Both PARP1 and DNA-PKcs are required for ERG-medi-
ated transcription and cell invasion, suggesting that both of
these cofactors are necessary for ERG-mediated prostate
cancer progression. Moreover, therapeutic inhibition of PARP1
preferentially sensitized ETS-overexpressing prostate cancer
xenografts compared to ETS-negative xenografts. Thus, similar
to the successful paradigm of targeting the BCR-ABL gene
fusion in CML with the small molecule kinase inhibitor imatinib
mesylate (Druker et al., 2001), one could envision targeting the
ETS-PARP1 axis in prostate cancer and possibly other ETS
gene fusion-dependent cancers. Although directly inhibiting
transcription factors, such as ERG, may be difficult, blocking
the function of regulatory cofactors, such as PARP1, is more
feasible and may represent a viable treatment paradigm in
cancer therapy.
In particular, PARP1 represents a very promising therapeutic
target. Based on its role in base excision repair, PARP1 hasbeen explored in both preclinical and clinical settings as a target
in tumors with deficiencies in double-stranded DNA repair, such
as mutations in BRCA1 and BRCA2 (Bryant et al., 2005; Farmer
et al., 2005). In these cancers, the inhibition of PARP1 in cells
with an inherent defect in homologous repair results in stalled
replication forks and subsequent cell death (Bryant et al., 2005;
Farmer et al., 2005). An initial phase I trial of the PARP inhibitor
Olaparib has suggested an excellent therapeutic response in
patients with BRCA1/2-deficient tumors from multiple organ
sites with most patients experiencing a large reduction in total
tumor volume (Fong et al., 2009). However, most cancers do
not harbor BRCA1/2 mutations; only 5%–6% of all breast
cancers are associated with an inherited BRCA1/2 gene muta-
tion (Malone et al., 1998), and only 3% of prostate tumors from
an Ashkenazi Jewish population of 832 patients were BRCA1/2
deficient (Gallagher et al., 2010).
Although PARP inhibitors can exploit the DNA-repair defects
of BRCA-deficient tumors to induce cell death, we now demon-
strate that they can also inhibit ETS gene fusion protein activity
by preventing ETS transcriptional activity, inhibiting ETS-associ-
ated invasion, and enhancing ETS-mediated DNA damage.
Future studies will help determine if, as with AR-mediated tran-
scription (Haffner et al., 2010), ETS-mediated transcription is
directly coupled to the induction of DNA damage. Importantly,
the potentiation of ETS-induced DNA damage by PARP inhibi-
tion is of particular clinical interest, analogous to the ‘‘synthetic
lethality’’ resulting from PARP inhibition in BRCA1/2-deficient
tumors. By suggesting that cancers driven by specific oncogenic
transcription factors may respond to PARP inhibition indepen-
dent of BRCA1/2 status, our data support the notion that multiple
tumor subtypes will be susceptible to PARP pharmacotherapy. It
is important to note that the company Sanofi-BiPAR recently
released a press report that their phase III trial assessing the
addition of their next generation PARP inhibitor, Iniparib, to
a gemcitabine-carboplatin regimen for patients with metastatic
triple-negative breast cancer, was negative for an overall survival
benefit (http://sanofi-aventis.mediaroom.com/index.php?s = 43
&item = 310). This is in direct contrast to the recently reported
phase II trial showing that the addition of Iniparib approximately
doubled overall survival in this setting (O’Shaughnessy et al.,
2011), and some questions about specificity have been raised
(Carey and Sharpless, 2011). Nonetheless, these results high-
light the importance of target selection; it is expected that
ongoing phase III trials assessing chemotherapy with or without
PARP inhibitor in BRCAmutant cancers (instead of a nonspecific
triple-negative breast cancer population) will be positive be-
cause the patient population is selected based on the presence
of the PARP inhibitor target—BRCA mutation (Ellisen, 2011).
Here, we have shown that Olaparib very specifically, and in
a dose-dependent manner, delays tumor growth of ETS-posi-
tive, but not ETS-negative, prostate cancer xenografts.
By exploiting the ETS:PARP1 interaction to selectively target
ETS-overexpressing xenografts, our studies significantly ex-
pand the total population of patients who could benefit from
PARP inhibition. Consequently, the data presented here also
have implications on the design of subsequent clinical trials
that will follow the recently reported phase I trial of Olaparib
(Fong et al., 2009). Although most trials will undoubtedly be de-
signed to target and subtype BRCA-deficient tumors, trialsCancer Cell 19, 664–678, May 17, 2011 ª2011 Elsevier Inc. 675
Cancer Cell
PARP1 Inhibition in ETS Positive Prostate Cancerdesigned in organ sites that are also known to harbor aberrantly
expressed ETS genes, such as breast, melanoma, Ewing’s
sarcoma, and especially prostate, should also subtype the
disease by ETS status. Based on the data presented here,
ETS-positive tumors are expected to respond with a higher
probability to PARP inhibition than ETS-negative tumors, poten-
tially making ETS status an important predictive biomarker. In
line with the observation that PARP inhibitors can significantly
increase themean overall survival of patients with triple-negative
breast cancer when added onto an existing regimen, our data
suggest that the best design for a clinical trial in hormone-refrac-
tory metastatic prostate cancer will be to add PARP inhibitors in
combination with chemotherapeutics known to potentiate the
effects of PARP inhibition such as TMZ.
Finally, the observation that gene fusions that drive the gross
overexpression of ETS genes also induce DNA double-strand
break formation provides additional mechanistic insight into
how ETS gene fusions drive cancer progression. Specifically,
by causing DNA double-strand breaks, ETS gene overexpres-
sion may also play a role in the gradual evolution of genomic re-
arrangements. This finding may explain why recurrent ETS gene
fusions were difficult to discover because ETS overexpression
simply leads to the accumulation of additional gene fusions,
only some of which will drive disease progression. In fact this
model may partially explain the clinical behavior of prostate
cancers that lie dormant for years only to spontaneously become
extremely aggressive.
EXPERIMENTAL PROCEDURES
Xenograft and Primary Human Xenograft Models
For human prostate cancer xenografts, written informed consent was obtained
before sample acquisition, and the sample was processed according to
a protocol approved by The University of Texas, MD Anderson Cancer Center
institutional review board. All procedures were approved by the University of
Michigan’s University Committee on Use and Care of Animals (UCUCA).
Expression profiling was performed using the Agilent Whole Human Genome
Oligo Microarray (Santa Clara, CA, USA) according to the manufacturer’s
protocol and described previously (Tomlins et al., 2007b).
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